New study shows: Carragos nasal spray relieves allergy symptoms

New study shows: Carragos nasal spray relieves allergy symptoms

The Marinomed Biotech AG has presented exciting new results on your nasal spray, according to a current message. This product combines the advantages of the natural substance of Carragelose with the gentle decongestant effect of Sorbitol. The resulting clinical data has now been published in the renowned International Journal of General Medicine and show promising results for patients with allergic runny nose.

The reported improvement in breathing in patients is particularly impressive. The clinical study, in which adults were tested with known allergies against grasses, demonstrated that a noticeable relief of the symptoms occurred after the first application of the spray. These results are particularly important, since the product can not only be the symptoms of an allergic reaction, but also that of a normal cold. Another advantage of the nasal spray is that it does not cause habituation effect that can often be observed in other decongestant medication.

clinical results and relevance

The randomized, double-blind crossover study in which adults aged 18 to 65 years of age exposed the participants in a controlled environment. The result was gratifying: the nasal air flow significantly improved in the subjects compared to the placebo group. These insights support the application of the product in the treatment of nasal interference, regardless of whether they are allergic or not.

"The results show that allergic patients can breathe significantly better after the first application. In addition, the product is also suitable for children from one year," said Eva Prieschl-Grassauer, the Chief Scientific Officer at Marinomed, and underlined the versatility of the application. These study results are not only groundbreaking for product development in marinomed, but could also help to open up new license opportunities.

The nasal spray, which has been available in a total of eleven countries since its introduction in 2018, uses the special properties of Carrelose. This substance is a polymer obtained from red algae, which not only makes breathing easier, but also offers effective protection against viruses. According to clinical studies, Carragelose can even reduce the transmission of viruses such as SARS-COV-2, which makes it a remarkable remedy in the area of respiratory diseases. More information about the advantages and the use of Carragelose can be found on the official Marinomed website

The Marinomed Biotech AG is an innovative company based in Korneuburg, Austria, which focuses on the development of patent -protected products in the areas of immunology and virology. The company has a promising product pipeline and is listed on the Vienna Stock Exchange. The efforts to comply with new medical regulations are another important step for the development and marketing of their products. Interested parties can view the current publication and further details on the Marinomed websites, such as the scientific publications that confirm the effectiveness of Carrelose

The publication of these results not only shows the progress of Marinomed Biotech AG in product development, but also emphasizes the relevance of innovative solutions in allergen treatment. With the versatility of the Carragelose spray, many patients could benefit from effective relief from their symptoms, whereby the company positions itself as an important player in the biotechnology sector.

For more detailed information about Carragelose and Marinomed Biotech AG, as well as its product portfolio, a look at the website www.marinomed.com .